Articles related to PROSTATE CANCER

Interim results from J&J’s Phase I study of JNJ-6420 highlight both promising efficacy in prostate cancer treatment and serious safety concerns, with 60% of patients experiencing severe adverse events.

A large-scale randomized controlled trial has identified significant prognostic factors for overall survival (OS) and cancer-specific survival (CSS) in localized prostate cancer, offering new insights into optimizing treatment strategies using surgery and radiotherapy.

This phase 2 study underscores the challenges in enhancing therapeutic outcomes in metastatic castration-resistant prostate cancer with AZD4635 combined with immunotherapy, indicating a minimal PSA response among treated patients.

In cases of prostate cancer post-aquablation therapy, managing residual tissue and persistent PSA levels poses significant challenges for surgical intervention, as detailed by Dr. Edward M. Schaeffer.

In a significant stride toward personalized medicine, researchers have utilized AI to unveil two distinct evotypes of prostate cancer, heralding a new era in the disease’s diagnosis and management. This pivotal discovery opens doors to tailored treatment strategies, potentially mitigating the adverse effects of over-treatment in prostate cancer.

Explore the potential of IS-002, an imaging agent that offers a new dimension in intraoperative prostate cancer detection, promising a more targeted approach to surgical intervention and patient management.